Immunotherapy for insulin-dependent diabetes mellitus in the "BB" rat.
We have previously reported that weekly administration of the adenosine deaminase inhibitor, 2'-deoxycoformycin (dCF), reduces the incidence of insulin-dependent diabetes mellitus (IDDM) in the BB Wistar rat, and this effect is likely due to immunosuppression by dCF. In the present study, we examined the effect of altering the dose and scheduling of dCF on prevention of IDDM in the BB rat. When rats were treated from day 25 of age with 2.5, 4, or 10 mg of dCF/kg/week, the percentage of diabetes-free animals at 120 days of age was 40, 60, and 80% respectively, compared with 10% for control animals, demonstrating increased protection against IDDM with increased dCF dose. Histological assessment of the pancreata from animals that became diabetic revealed a marked mononuclear infiltrate and a loss of positive staining for beta cell granules. In contrast, pancreata from animals that remained diabetes-free appeared normal. Protection against IDDM by dCF was time dependent and only occurred if treatments were initiated by day 30 of age. In addition, the protective effect persisted after drug withdrawal. Further studies are required to determine the optimum duration of therapy with dCF to prevent IDDM and to examine the immunological mechanism responsible for this effect.
Thliveris
J A
JA
Department of Human Anatomy and Cell Science, University of Manitoba, Winnipeg, Canada. Thliveri@bldghsc.lan1.umanitoba.ca
Begleiter
A
A
Manchur
D
D
Johnston
J B
JB
D000375:Aging; D000818:Animals; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology* / Q000473:pathology / Q000517:prevention & control*; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D010179:Pancreas / Q000473:pathology; D015649:Pentostatin / Q000008:administration & dosage* / Q000627:therapeutic use; D051381:Rats; D011913:Rats, Inbred BB
D007166:Immunosuppressive Agents; D015649:Pentostatin